UBE2V2: A Protein with existing biological functions and potential as a drug target

Target Name: UBE2V2

NCBI ID: G7336

UBE2V2

UBE2V2: A Protein with existing biological functions and potential as a drug target

UBE2V2, also known as enterocyte differentiation-promoting factor 1, is a protein that plays a crucial role in the development and maintenance of normal intestinal epithelial cells. It is a key regulator of cell proliferation and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative disorders, and developmental defects.

In addition to its role in cell biology, UBE2V2 is also a potential drug target. Researchers have identified several potential small molecules that can inhibit UBE2V2 activity and are currently in the process of testing these compounds for their potential therapeutic applications.

One of the most promising compounds is a compound called BAY 94-9234, which is a inhibitor of the protein kinase PDK4. PDK4 is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative disorders, and developmental defects. UBE2V2 is a known target for PDK4, and researchers have used this to develop a relationship between UBE2V2 and PDK4.

Research has shown that UBE2V2 and PDK4 are highly co-expressed in a variety of tissues, including intestinal epithelial cells, and that they are involved in many of the same signaling pathways. This suggests that UBE2V2 may be a good candidate for inhibiting PDK4 activity and potentially treating a variety of diseases.

Another promising compound that is being tested for its effects on UBE2V2 is called JNJ-752652. This compound is a small molecule inhibitor of the protein tyrosine kinase PDGFR. PDGFR is a kinase that is involved in many signaling pathways, including those that regulate cell proliferation and differentiation.

Research has shown that UBE2V2 and PDGFR are also highly co-expressed in a variety of tissues, including intestinal epithelial cells, and that they are involved in many of the same signaling pathways. This suggests that UBE2V2 may be a good candidate for inhibiting PDGFR activity and potentially treating a variety of diseases.

In addition to its potential as a drug target, UBE2V2 is also a valuable biomarker for a number of diseases. Because it is involved in the regulation of cell proliferation and differentiation, it is often used as a marker for tissues that are undergoing rapid growth and development, such as those that are derived from the gut lining.

Research has shown that UBE2V2 levels are often elevated in a variety of diseases, including cancer, neurodegenerative disorders, and developmental defects. This suggests that UBE2V2 may be a useful biomarker for these diseases and that it may be a promising target for drug development.

Overall, UBE2V2 is a protein that plays a crucial role in the development and maintenance of normal intestinal epithelial cells. It is also a potential drug target and a valuable biomarker for a number of diseases. Further research is needed to fully understand its role and potential as a therapeutic agent.

Protein Name: Ubiquitin Conjugating Enzyme E2 V2

Functions: Has no ubiquitin ligase activity on its own. The UBE2V2/UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through 'Lys-63'. This type of poly-ubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage

The "UBE2V2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2V2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets